TKTL1 and soft tissue sarcoma: Targeting receptor tyrosine kinases. No recurrent oncogenic tyrosine kinase receptor (TKR) alterations have been identified in ULMs until now, which limits the utilization of highly effective and selective TKR inhibitors identified in other soft tissue sarcomas.